" class="no-js "lang="en-US"> Rivus Pharmaceuticals - Medtech Alert
Sunday, May 26, 2024
Rivus Pharmaceuticals | Pharmtech Focus

Rivus Pharmaceuticals

About Rivus Pharmaceuticals

Rivus Pharmaceuticals

Rivus Pharmaceuticals, Inc., a leader in mitochondrial biology, is dedicated to improving cardio-metabolic health by advancing a new class of medicines, Controlled Metabolic Accelerators (CMAs). Harnessing a natural metabolic process, CMAs target a significant risk factor for these diseases – obesity, the result of excess fat accumulation in the body. Rivus’ first-in-class small molecule therapy, HU6, represents a tremendous opportunity to empower patients on their journey to better health when facing a broad range of conditions, including obesity, heart failure with preserved ejection fraction (HFpEF), type 2 diabetes, and Nonalcoholic fatty liver disease (NAFLD)/Nonalcoholic steatohepatitis (NASH).

Related Story

Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders

September 23 2022

Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the […]